Current Report Filing (8-k)
July 15 2021 - 8:17AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 12, 2021
GUARDION
HEALTH SCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-38861
|
|
47-4428421
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
15150
Avenue of Science, Suite 200
San
Diego, CA 92128
(Address
of principal executive offices, including zip code)
(858)
605-9055
Registrant’s
telephone number, including area code
Not
Applicable
|
(Former
name or former address, if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.001 per share
|
|
GHSI
|
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
As
previously reported by Guardion Health Sciences, Inc. (the “Company”) on a Current Report on Form 8-K filed with the Securities
and Exchange Commission on May 24, 2021, Andrew Schmidt, the Chief Financial Officer of the Company, provided written notice of his decision
not to renew the term of his employment with the Company, resulting in his employment with the Company terminating effective as of July
20, 2021, unless earlier terminated pursuant to the terms of Mr. Schmidt’s employment agreement. Effective as of July 12, 2021,
Mr. Schmidt effectively terminated his employment with the Company and the related employment agreement without providing any advance
or further notice to the Company.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
GUARDION
HEALTH SCIENCES, INC.
|
Date:
July 15, 2021
|
|
|
|
By:
|
/s/
Bret Scholtes
|
|
Name:
|
Bret
Scholtes
|
|
Title:
|
Chief
Executive Officer
|
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Apr 2023 to Apr 2024